MGEN - Miragen Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
5.29
+0.06 (+1.15%)
At close: 4:00PM EDT

5.29 0.00 (0.00%)
After hours: 4:00PM EDT

Stock chart is not supported by your current browser
Previous Close5.23
Open5.20
Bid5.18 x 2900
Ask5.88 x 800
Day's Range5.04 - 5.34
52 Week Range4.38 - 10.70
Volume112,155
Avg. Volume138,526
Market Cap162.658M
Beta (3Y Monthly)1.82
PE Ratio (TTM)N/A
EPS (TTM)-1.02
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est17.90
Trade prices are not sourced from all markets
  • GlobeNewswire17 days ago

    miRagen Therapeutics Announces the Presentation of Data From Preclinical Studies Demonstrating the Potential Anti-Fibrotic Effect of Remlarsen in the Cornea at the 2018 OLIGO Meeting in Seattle, WA

    Remlarsen treatment increased corneal re-epithelialization, decreased corneal scar formation, and repressed the expression of several pro-fibrotic genes when compared to placebo treated eyes in a preclinical model of corneal ulceration. Remlarsen or a fluorescently labeled version of the product candidate were administered topically to the rat cornea in the context of a corneal ulcer.

  • GlobeNewswire2 months ago

    miRagen Therapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update

    BOULDER, Colo., Aug. 07, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today reported second quarter 2018 financial results and provided a corporate update. “This is an exciting time for microRNA-based therapeutics and I am very proud of what our team at miRagen has accomplished,” said William S. Marshall, Ph.D., President and Chief Executive Officer of miRagen Therapeutics. “We are focused on building a sustainable company with the potential to deliver multiple product candidates for patients in need.  During the quarter, we announced progress on each of our three clinical stage product candidates.  We were encouraged by the initial efficacy data for cobomarsen in patients with ATLL and pleased to have initiated two new clinical trials during the quarter, including a Phase 2 trial for remlarsen (also known as MRG-201) and our second Phase 1 trial of MRG-110 in collaboration with Servier.

  • ACCESSWIRE2 months ago

    Miragen Therapeutics, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 7, 2018 / Miragen Therapeutics, Inc. (NASDAQ: MGEN ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 7, 2018 at 4:30 PM Eastern ...

  • GlobeNewswire2 months ago

    miRagen Therapeutics and The Leukemia & Lymphoma Society® Enter Into an Agreement to Facilitate the Development of Cobomarsen in Cutaneous T-Cell Lymphoma

    BOULDER, Colo. and RYE BROOK, N.Y., Aug. 06, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, and The Leukemia & Lymphoma Society® (LLS) today announced that they entered into an agreement providing for collaboration and funding intended to support the development of miRagen’s cobomarsen (also known as MRG-106), a microRNA-155 inhibitor, for the treatment of patients with the mycosis fungoides (MF) form of cutaneous T-cell lymphoma (CTCL).  There are approximately 16,000-20,000 people in the U.S. with mycosis fungoides. LLS will provide up to $5 million through the purchase of miRagen common stock to help support the SOLAR trial.

  • GlobeNewswire3 months ago

    miRagen Therapeutics to Present at the 2018 Wedbush PacGrow Healthcare Conference

    BOULDER, Colo., July 31, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, announced today that William S. Marshall, Ph.D., President and Chief Executive Officer, is scheduled to provide a company overview at the 2018 Wedbush PacGrow Healthcare Conference at 10:20 am EDT on Tuesday, August 14, 2018, at the Le Parker Meridien Hotel in New York.

  • GlobeNewswire3 months ago

    miRagen Therapeutics to Report Second Quarter 2018 Financial Results and Host Conference Call on August 7, 2018

    BOULDER, Colo., July 25, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, will host a conference call on Tuesday, August 7, 2018, at 4:30 p.m. ET to discuss its financial results for the second quarter 2018. The call will also be webcast and can be accessed from the Investors and Media section of the Company’s website at www.miragen.com.  A replay of this conference call will be available on miRagen’s website approximately one hour after the event.

  • Should Miragen Therapeutics Inc’s (NASDAQ:MGEN) Recent Earnings Decline Worry You?
    Simply Wall St.5 months ago

    Should Miragen Therapeutics Inc’s (NASDAQ:MGEN) Recent Earnings Decline Worry You?

    In this commentary, I will examine Miragen Therapeutics Inc’s (NASDAQ:MGEN) latest earnings update (31 December 2017) and compare these figures against its performance over the past couple of years, asRead More...

  • ACCESSWIRE7 months ago

    Blog Exposure - Foundation Medicine Collaborated with Chugai for Commercialization of FoundationOne CDx(TM) in Japan

    Stock Monitor: Miragen Therapeutics Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 20, 2018 / Active-Investors.com has just released a free research report on Foundation Medicine, Inc. (NASDAQ: ...

  • ACCESSWIRE7 months ago

    Miragen Therapeutics, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 14, 2018 / Miragen Therapeutics, Inc. (NASDAQ: MGEN ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 14, 2018, at 4:30 PM Eastern ...